Plain-English translation of NCT07398664 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two treatments for people with head and neck cancer that has come back or spread to other parts of the body. The first treatment is , a special virus that has been designed to attack cancer cells while leaving healthy cells alone. The second is a catheter procedure that blocks blood flow to tumors while delivering chemotherapy directly to the cancer, and researchers believe combining these two approaches may work better together than either one alone.
People with recurrent or metastatic head and neck cancer face a grim outlook, with survival times of only 7 to 9 months on average, and current treatments haven't been very effective. This trial exists to test whether combining this medication with a well-established procedure could offer these patients a new, more promising option.
You likely qualify if…
You likely don't qualify if…
You would receive the combination treatment of and the catheter-based procedure at the study center. The exact schedule of visits and treatment sessions will be explained to you, but you will need to commit to following the treatment plan and attending all scheduled appointments. Your doctors will monitor you closely during and after treatment to watch for side effects and to see how well the treatment is working.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
West China Hospital
Enrollment target
~20 participants
Started
March 2026
Primary completion
June 2028
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tao Hai
West China Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.